| |
| |
| Exchange: |
Over The Counter |
| Security
Type: |
Common |
| Shares
Out: |
570,750,000 |
| Market
Cap: |
76.54(M) |
| Last
Volume: |
3,709,408 |
Avg
Vol: |
3,188,549 |
| 52
Week Range: |
$0.1356 - $0.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CytoDyn is a clinical-stage biotechnology company focused on the clinical development of treatments for multiple therapeutic indications based on its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor. Leronlimab is being investigated as a viral entry inhibitor for Human Immunodeficiency Virus. Leronlimab is also being studied in oncology, as well as other therapeutic indications, including coronavirus disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Naydenov Jordan G |
Director |
– • – |
2020-11-02 |
4 |
B |
$2.57 |
$497,295 |
D/D |
193,500 |
6,451,323 |
2.39 |
-4% |
|
| Naydenov Jordan G |
Director |
– • – |
2020-10-23 |
4 |
B |
$2.49 |
$298,308 |
D/D |
120,000 |
6,257,823 |
2.39 |
65% |
|
| Colachis Arian |
GC and Corporate Secretary |
• – – |
2020-10-23 |
4 |
B |
$2.50 |
$25,000 |
D/D |
10,000 |
80,000 |
2.74 |
65% |
|
| Rahman Mahboob U |
Chief Scientific Officer |
• – – |
2020-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
284,081 |
|
- |
|
| Ray Nitya G. |
Chief Technology Officer |
• – – |
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Kelly Scott A. |
Chairman & CMO |
• • – |
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
1,741,052 |
|
- |
|
| Pourhassan Nader |
President & CEO |
• • – |
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
500,000 |
1,574,930 |
|
- |
|
| Colachis Arian |
GC and Corporate Secretary |
• – – |
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
70,000 |
|
- |
|
| Kelly Scott A. |
Chairman & CMO |
• • – |
2020-08-28 |
4 |
GA |
$0.00 |
$0 |
I/I |
74,800 |
97,980 |
|
- |
|
| Kelly Scott A. |
Chairman & CMO |
• • – |
2020-08-28 |
4 |
GD |
$0.00 |
$0 |
I/I |
74,800 |
616,408 |
|
- |
|
| Pourhassan Nader |
President & CEO |
• • – |
2020-07-31 |
4 |
D |
$4.97 |
$778,153 |
D/D |
(156,570) |
1,074,930 |
|
- |
|
| Pourhassan Nader |
President & CEO |
• • – |
2020-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
323,157 |
1,231,500 |
|
- |
|
| Kelly Scott A. |
Chief Medical Officer |
• • – |
2020-05-04 |
4 |
OE |
$0.52 |
$4,334 |
D/D |
8,334 |
1,566,052 |
|
- |
|
| Pourhassan Nader |
President & CEO |
• • – |
2020-05-04 |
4 |
S |
$2.79 |
$3,353,090 |
D/D |
(1,201,652) |
908,343 |
|
-49% |
|
| Pourhassan Nader |
President & CEO |
• • – |
2020-05-04 |
4 |
OE |
$0.39 |
$12,064 |
D/D |
30,933 |
2,109,995 |
|
- |
|
| Kelly Scott A. |
Chairman & CMO |
• • – |
2020-05-01 |
4/A |
OE |
$0.39 |
$651,649 |
D/D |
1,439,548 |
2,757,718 |
|
- |
|
| Kelly Scott A. |
Chief Medical Officer |
• • – |
2020-05-01 |
4 |
S |
$3.26 |
$3,912,480 |
D/D |
(1,200,000) |
1,557,718 |
|
-22% |
|
| Kelly Scott A. |
Chief Medical Officer |
• • – |
2020-05-01 |
4 |
OE |
$0.39 |
$510,399 |
D/D |
1,189,548 |
2,757,718 |
|
- |
|
| Kelly Scott A. |
Chief Medical Officer |
• • – |
2020-05-01 |
4 |
B |
$0.57 |
$141,250 |
D/D |
250,000 |
1,847,302 |
2.81 |
22% |
|
| Pourhassan Nader |
President & CEO |
• • – |
2020-05-01 |
4 |
S |
$3.26 |
$4,569,132 |
D/D |
(1,399,685) |
2,079,062 |
|
-22% |
|
| Pourhassan Nader |
President & CEO |
• • – |
2020-04-30 |
4 |
S |
$3.53 |
$7,838,688 |
D/D |
(2,219,837) |
3,478,747 |
|
-39% |
|
| Pourhassan Nader |
President & CEO |
• • – |
2020-04-30 |
4 |
OE |
$0.39 |
$3,779,994 |
D/D |
5,381,167 |
5,698,584 |
|
- |
|
| Patel Samir Rashmikant |
Director |
– • – |
2020-04-17 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
7,218,874 |
|
- |
|
| Welch David F |
Director |
– • – |
2020-04-01 |
4 |
OE |
$0.50 |
$1,129,551 |
I/I |
2,259,102 |
9,513,417 |
|
- |
|
381 Records found
|
|
Page 4 of 16 |
|
|
